{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002793","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.461593+00:00","generated_at":"2026-06-27T02:00:43.111954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Treace Q4 revenue $33.4M (+39% YoY); FY22 guidance $125-130M (32-38% growth)","bullets":["Full-year 2021 revenue $94.4M (+65% YoY); net loss ($20.7M) or ($0.43)/share vs. ($4.3M) in 2020.","Q4 gross margin 81.1% (+220 bps YoY); operating expenses $32.7M from $15.4M in Q4 2020.","Cash $105.8M at Dec 31; FY22 revenue guided $125-130M.","ALIGN3D clinical data: 0.9% recurrence at 12 months, 0.0% at 24 months post-Lapiplasty.","Expanded patent portfolio: 32 granted US patents, over 30 pending applications."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002793","json":"https://secwatch.observer/filing/0000950170-22-002793.json","markdown":"https://secwatch.observer/filing/0000950170-22-002793.md","text":"https://secwatch.observer/filing/0000950170-22-002793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017022002793/0000950170-22-002793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017022002793/tmci-20220303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:00:43.111954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}